1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,490 | 0,590 | 21:58 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | GENENTA SCIENCE SPA: Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs | 689 | GlobeNewswire (Europe) | MILAN, March 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian... ► Artikel lesen | |
| 24.03. | GENENTA SCIENCE SPA: Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini | 321 | GlobeNewswire (Europe) | MILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian... ► Artikel lesen | |
| 13.03. | GENENTA SCIENCE SPA: Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University | 489 | GlobeNewswire (Europe) | MILAN, March 13, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge (Nasdaq: SAEN)1, a strategic industrial consolidator focused on biotech, defense, aerospace... ► Artikel lesen | |
| 28.02. | Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business | 4 | Insider Monkey | ||
| 27.02. | GENENTA SCIENCE SPA: Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform | 552 | GlobeNewswire (Europe) | MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge (Nasdaq: SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace... ► Artikel lesen | |
| 27.01. | Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments | 4 | Benzinga.com | ||
| 27.01. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 27.01. | GENENTA SCIENCE SPA: Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator | 381 | GlobeNewswire (Europe) | Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian CompaniesATC - a Defense-Sector Company: First Industrial... ► Artikel lesen | |
| GENENTA SCIENCE Aktie jetzt für 0€ handeln | |||||
| 19.12.25 | GENENTA SCIENCE SPA: Genenta Science Provides Update on CEO Ownership | 322 | GlobeNewswire (Europe) | MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors... ► Artikel lesen | |
| 24.11.25 | Aktie von Genenta Science schießt nach Update zu Glioblastom-Studie in die Höhe | 11 | Investing.com Deutsch | ||
| 24.11.25 | GENENTA SCIENCE SPA: Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial | 368 | GlobeNewswire (Europe) | MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic... ► Artikel lesen | |
| 28.10.25 | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.10.25 | Aktie von Genenta Science stürzt nach 15-Millionen-Dollar-Kapitalerhöhung ab | 13 | Investing.com Deutsch | ||
| 27.10.25 | Genenta Science stock plunges after $15 million ADS offering | 2 | Investing.com | ||
| 27.10.25 | Genenta Science jumps on $15M direct offering | 3 | Seeking Alpha | ||
| 27.10.25 | Genenta Science raises $15 million in ADS offering at $3.50 per share | 4 | Investing.com | ||
| 27.10.25 | GENENTA SCIENCE SPA: Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares | 2 | GlobeNewswire (USA) | ||
| 24.10.25 | Genenta Science Stock Jumps 85% On Strategic Collaboration With Anemocyte | 10 | RTTNews | ||
| 24.10.25 | Genenta Science stock soars on strategic LVV Plasmid DNA collaboration | 6 | Investing.com | ||
| 24.10.25 | Genenta and Anemocyte partner on lentiviral vector plasmid DNA tech | 17 | Investing.com |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,350 | +0,91 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ERASCA | 16,340 | -4,05 % | What's Driving Erasca (ERAS)'s Nearly 355% YTD Return | ||
| BIONTECH | 82,20 | +0,92 % | Biotech-Werte im Check: Warum Bioxyne, Newron und BioNTech jetzt auf Substanz statt Hoffnung setzen | ||
| ALLOGENE THERAPEUTICS | 3,150 | +15,81 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,185 | +9,96 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| EVOTEC | 4,700 | +3,84 % | Evotec-Aktie profitiert von Milliarden-Deal: Gilead kauft Tubulis | Der US-Pharmakonzern Gilead setzt seine Einkaufstour im Biotech-Sektor fort und übernimmt das deutsche Krebsforschungsunternehmen Tubulis für bis zu fünf Milliarden Dollar. Die Transaktion zeigt, wie... ► Artikel lesen | |
| CG ONCOLOGY | 67,55 | -0,21 % | CG Oncology, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 317,84 | +1,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy | Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,925 | +9,84 % | Healthcare quant check: RLAY and TNGX lead Seeking Alpha's top picks ahead of Q1 earnings | ||
| ADMA BIOLOGICS | 10,375 | +6,96 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| ARCELLX | 114,88 | +0,04 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,805 | +1,22 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| MODERNA | 43,000 | -1,06 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 88,73 | +4,25 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,330 | +2,47 % | Relay Therapeutics, Inc.: Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 |
GENENTA SCIENCE SPA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,92 % bei einem Aktienkurs von 0,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENENTA SCIENCE SPA ADR finden Sie auf Wallstreet Online.